Skip to main content

Definitive Healthcare launches Monocl ExpertInsight 2.0 and ExpertGO mobile app

Written by Customer Service on . Posted in Public Companies.

Medical affairs teams can now access the scientific activities of nearly 13 million experts globally across all therapeutic areas in a single platform

FRAMINGHAM, Mass., June 14, 2022 (GLOBE NEWSWIRE) — Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced the general availability of Monocl ExpertInsight 2.0, the next generation of the company’s expert identification product, and a new mobile app, Monocl ExpertGO. These new offerings give medical affairs professionals access to nearly 13 million expert profiles globally so they can more quickly identify and engage the right scientific experts to provide critical insights that can accelerate the drug development process.

Monocl ExpertInsight 2.0 provides an optimized user experience that helps medical affairs teams increase productivity, streamline workflows and develop more informed medical strategies. Monocl ExpertInsight 2.0 equips medical affairs teams with:

  • Live filters that provide an overview of scientific activity with real-time updates and filters by expert and/or therapeutic area
  • Advanced search functionality to identify experts more easily in specific disease areas
  • Dynamic key opinion leader (KOL) mapping, which displays the location of experts in granular detail down to the city level

Existing clients will get access to these new features at no additional cost as part of their existing Monocl ExpertInsight subscription.

“We’re passionate about helping medical affairs teams find the right experts who can help accelerate time to market for a new drug or medical device,” said Robert Musslewhite, president of Definitive Healthcare. “With today’s release, our customers now have access to nearly 13 million key opinion leaders, and they can get the insights they need on those leaders from any location with our new ExpertGO mobile app.”

The new ExpertGO mobile app gives field medical leaders and medical science liaisons (MSLs) access to the latest intelligence, scientific activity and collaborator insights on experts around the globe. The ability to access these insights when and where needed is particularly valuable for MSLs, most of whom spend the majority of their time outside of the office, where they are visiting with experts in person.

ExpertGO will be available to download on Apple and Android devices in late June at no additional cost to existing ExpertInsight customers.

As part of this latest release, Definitive Healthcare also added Brazilian expert data to the Monocl ExpertInsight database to help life sciences teams gain a deeper understanding of the South American market. The new data covers intelligence on Brazilian healthcare professionals’ (HCPs) location and specialty, using claims data.

About Definitive Healthcare

At Definitive Healthcare, our passion is to transform data, analytics and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities and people, so they can shape tomorrow’s healthcare industry. Our SaaS platform creates new paths to commercial success in the healthcare market, so companies can identify where to go next. Learn more at definitivehc.com.

Investor Relations Contact:
Brian Denyeau
ICR for Definitive Healthcare
brian.denyeau@icrinc.com
646-277-1251

Media Contacts:
Danielle Johns
djohns@definitivehc.com

Highwire PR
definitivehealthcare@highwirepr.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.